Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "Jubilant-Pharmova-Limited"

29 News Found

Jubilant HollisterStier announces CAD 100 mn for Montreal facility
News | July 01, 2022

Jubilant HollisterStier announces CAD 100 mn for Montreal facility

The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million


Jubilant HollisterStier enters into agreement of $149.6 mn with US Govt to expand critical vaccine manufacturing capacity
News | June 01, 2022

Jubilant HollisterStier enters into agreement of $149.6 mn with US Govt to expand critical vaccine manufacturing capacity

This agreement is in addition to the $92 million filling line expansion announced in November 2021


Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'
News | February 19, 2022

Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'

Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).


Jubilant Pharmova’s Roorkee facility placed under import alert
News | July 16, 2021

Jubilant Pharmova’s Roorkee facility placed under import alert

The company will engage with the agency to resolve the import alert at the earliest and ensure cGMP compliance.


Jubilant HollisterStier to manufacture COVID-19 Vaccine COVAXIN in US
News | June 15, 2021

Jubilant HollisterStier to manufacture COVID-19 Vaccine COVAXIN in US

Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets


Jubilant to invest US $92 mn to expand sterile injectable capacity
News | June 01, 2021

Jubilant to invest US $92 mn to expand sterile injectable capacity

This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology


CRISIL assigns 'Positive' outlook to Jubilant Pharmova's long-term rating
News | May 11, 2021

CRISIL assigns 'Positive' outlook to Jubilant Pharmova's long-term rating

The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.


Jubilant Pharma wins over Bracco's legal appeals in the US Court of Appeals
News | May 10, 2021

Jubilant Pharma wins over Bracco's legal appeals in the US Court of Appeals

Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office


Jubilant Pharmova Q3FY21 consolidated PAT at Rs. 309.93 Cr
News | February 08, 2021

Jubilant Pharmova Q3FY21 consolidated PAT at Rs. 309.93 Cr

The company posted net profit of Rs.203.38 crores for the period ended December 31, 2019.